[Skip to Navigation]
Views 1,081
Citations 0
April 1, 2021

Carfilzomib-Based 3-Drug Regimens for Newly Diagnosed Multiple Myeloma—All That Glitters Is Not Gold

Author Affiliations
  • 1Division of Hematology Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston
  • 2Division of Internal Medicine, Weiss Memorial Hospital, Chicago, Illinois
  • 3Hematology, Oncology, Blood & Marrow Transplantation, Multiple Myeloma Program, Taussig Cancer Center, Cleveland Clinic, Ohio
JAMA Oncol. 2021;7(7):967-968. doi:10.1001/jamaoncol.2021.0174
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words